MacroGenics Inc (NASDAQ:MGNX) SVP Eric Blasius Risser sold 4,489 shares of the business’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $25.47, for a total value of $114,334.83. Following the sale, the senior vice president now directly owns 44,957 shares in the company, valued at $1,145,054.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Blasius Risser also recently made the following trade(s):

  • On Thursday, July 2nd, Eric Blasius Risser sold 3,100 shares of MacroGenics stock. The stock was sold at an average price of $30.00, for a total transaction of $93,000.00.
  • On Wednesday, June 24th, Eric Blasius Risser sold 500 shares of MacroGenics stock. The shares were sold at an average price of $28.49, for a total transaction of $14,245.00.
  • On Wednesday, May 6th, Eric Blasius Risser sold 8,032 shares of MacroGenics stock. The stock was sold at an average price of $20.95, for a total transaction of $168,270.40.

Shares of MGNX opened at $26.75 on Friday. The firm has a market cap of $1.34 billion, a PE ratio of -8.66 and a beta of 2.84. The firm’s 50 day moving average price is $27.09 and its 200 day moving average price is $15.50. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.93 and a current ratio of 4.93. MacroGenics Inc has a twelve month low of $4.04 and a twelve month high of $32.18.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02). MacroGenics had a negative return on equity of 62.43% and a negative net margin of 222.14%. On average, sell-side analysts anticipate that MacroGenics Inc will post -3.07 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Swiss National Bank increased its position in MacroGenics by 1.3% during the first quarter. Swiss National Bank now owns 90,100 shares of the biopharmaceutical company’s stock worth $524,000 after buying an additional 1,200 shares during the last quarter. Citigroup Inc. increased its holdings in shares of MacroGenics by 7.1% during the 1st quarter. Citigroup Inc. now owns 38,802 shares of the biopharmaceutical company’s stock valued at $226,000 after acquiring an additional 2,568 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of MacroGenics by 0.4% during the 4th quarter. Nuveen Asset Management LLC now owns 706,895 shares of the biopharmaceutical company’s stock valued at $7,691,000 after acquiring an additional 3,007 shares during the last quarter. Marshall Wace North America L.P. acquired a new stake in MacroGenics in the 1st quarter worth approximately $59,000. Finally, Great West Life Assurance Co. Can bought a new stake in MacroGenics during the fourth quarter worth approximately $35,000. 91.25% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have issued reports on the stock. HC Wainwright boosted their target price on shares of MacroGenics from $22.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. SVB Leerink lifted their price target on MacroGenics from $15.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, May 29th. BidaskClub downgraded MacroGenics from a “buy” rating to a “hold” rating in a research note on Friday, July 17th. Zacks Investment Research upgraded MacroGenics from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Wednesday. Finally, Morgan Stanley upped their target price on MacroGenics from $6.00 to $11.00 and gave the company an “underweight” rating in a report on Wednesday, July 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and fourteen have assigned a buy rating to the stock. MacroGenics has an average rating of “Buy” and an average target price of $29.69.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Featured Story: Understanding Analyst Recommendations

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.